Aesthetics attended the eighth Alma Academy on Thursday May 22-23 in Dubrovnik, Croatia.
The event gathered nearly 400 physicians and partners from over 46 countries, marking one of Alma’s largest global educational event to date. This year’s summit featured 19 international speakers, including Professor Ofir Artzi, Dr Pina Panchal, Dr Fatima Aguero and Dr Chytra Anand.
In line with this year’s theme, ‘The Art of the Patient’, the topics covered skin ageing, pigmentation, scarring, skin tightening and rejuvenation. In an exclusive conversation with the Aesthetics Journal, Lior Dayan, Alma CEO, and chief marketing officer, Talta Burgan, shared insights into the company’s latest Alma IQ technology and how it aims to reshape digital consultations within the aesthetics space.
During the interview, Aesthetics posed questions about Alma IQ’s features, its clinical value and its role in supporting the specialty’s move towards personalisation and non-invasive treatments. Explaining what differentiates Alma IQ from other digital consultation tools, Dayan said, “It’s preloaded with a very complicated clinical metric, which generates the personalised aesthetic recipe for each on the patients.”
According to the company, the system incorporates patented light-filtering technology intended to capture skin topography and accommodate a range of skin tones, including darker phototypes. According to Dayan, the design of the light distribution contributes to the accuracy of visual assessments made through the device.
Alma IQ aims to support real-time clinical decisions by suggesting appropriate treatment pathways – such as the correct laser or energy-based applicator – based on both visual data and patient-reported factors. “It’s about giving the doctor better tools to succeed,” said Burgan.
“Not just showing a before-and-after photo, but guiding the next step of treatment.” The technology also aims to support operational efficiency. “It allows the doctor to be very precise, but also to delegate,” Dayan explained.
When asked how Alma IQ fits into Alma’s long-term strategy, Dayan hinted at a broader ecosystem in development. “Soon, you’ll be hearing about injectables and skincare that will also connect to the AI. Everything will talk the same language – clinically and technologically.”
This ambition reflects wider trends across the aesthetics sector, particularly the growing demand for non-invasive, personalised solutions. “Patients today are very different,” said Burgan. “They want treatments tailored not just to their skin, but to their lifestyle – how much downtime they can take, how much pain they’re willing to tolerate.”
Alma’s approach, they explained, is rooted in the belief that innovation must align with both clinical value and practical usability. “It’s not enough to just put technology in the basket,” said Dayan. “You have to connect the dots — operationally, clinically and across the patient journey.”
